mRNA, TFF, And Next Steps To Tackle mRNA Therapeutic Challenges
Source: Roche CustomBiotech
Which specific steps do you consider the most challenging in mRNA therapeutic development? Hundreds of viewers tackled the question during the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development. Expert panelists Patrick Baumhof, SVP of Technology at CureVac and Christian Dohmen, Senior Director of Formulation & Aerosol Research at Ethris provided commentary, addressed audience questions on tangential flow filtration and lyophilization, and shared thoughts on new technologies in mRNA therapeutic development.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Roche CustomBiotech
This website uses cookies to ensure you get the best experience on our website. Learn more